Lymph node spread in the short gastric mesentery after total gastrectomy for stomach cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls patients with primary gastric adenocarcinoma who undergo total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. During surgery the short gastric mesenteries (No.4sa and No.10 groups) will be anatomically separated and submitted for pathological examination. Pathologists will record lymph node counts and positivity rates for each short gastric mesentery and the team will analyze correlations with tumor location and stage. The goal is to generate evidence to help standardize which short gastric mesenteric lymph nodes should be removed during total gastrectomy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged older than 18 years and younger than 85 years
2. Primary gastric adenocarcinoma confirmed by preoperative pathology result
3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
4. Patients who received total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
5. American Society of Anesthesiologists (ASA) class I, II, or III
6. Written informed consent

Exclusion Criteria:

1. Negative preoperative biopsy
2. Too late tumour stage or metastasis (cT4b/M1)
3. BMI\>30 kg/m2
4. previous neoadjuvant chemotherapy or radiotherapy
5. Previous upper abdominal surgery
6. Combined with other malignant diseases
7. Reject operation

Where it's running

• Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Tao Wang, Ph.d
• Email: 15002740874@163.com
• Phone: +86-197-068-25286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gastric Cancer Clinicobiological Cohort Study

  This study tests the tumor microenvironment in gastric and gastroesophageal junction cancers from patients who had surgery after standard neoadjuvant chemotherapy at a single center.

  Recruiting Centre Leon Berard · Lyon · NCT07787052

• GEH300079 (68Ga) PET/CT scan to detect peritoneal carcinomatosis in colorectal, gastric, ovarian, and pancreatic cancers (PERISCOPE)

  This will test whether a GEH300079 (68Ga) PET/CT scan can detect peritoneal carcinomatosis in adults with colorectal, gastric, ovarian, or pancreatic ductal adenocarcinoma who have known or suspected peritoneal disease.

  Recruiting Phase 2/3 GE Healthcare · Grand Rapids, Michigan and 1 other locations · NCT07219238

• Link between psychological distress and immune therapy response in gastric cancer

  We will see if psychological distress influences how well immune checkpoint inhibitors work in adults with gastric adenocarcinoma receiving preoperative immunotherapy before surgery.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07003334

• Robotic removal of stomach tumors after pre-surgery chemotherapy for advanced gastric cancer

  This trial tests whether robotic stomach cancer surgery after 3–4 cycles of preoperative therapy is safe and helps people with stage III resectable gastric or gastroesophageal junction adenocarcinoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06895447

• Using deep learning and Raman spectroscopy for early cancer diagnosis

  This study is trying to see if a new deep learning tool using blood samples can help spot early signs of different types of cancer, like colorectal and gastric cancers, in both healthy people and those already diagnosed.

  Recruiting at 4 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Nanchang, Jiangxi and 3 other locations · NCT06822413

• QL1706 combined with SOX for treating advanced gastric cancers

  This study is testing if a new treatment combining QL1706 and SOX can help people with advanced stomach cancer before surgery and improve their chances of recovery.

  Recruiting Phase 1/2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06766305

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.